We also have a number of other plenary and parallel sessions which include: estimands, toxicology, biosimilars, quantifying effect sizes, soft skills training, animated data, regulatory hot topics and many more with speakers from industry, academia and regulatory agencies, including Lisa LaVange (Director of the Office of Biostatistics in the Center for Drug Evaluation and Research at the USA FDA).
A draft agenda will be released later this year along with the 2017 Conference app. Please see the registration brochure for more information about sessions, speakers and prices.
Due to popular demand, we are increasing the number of oral presentations from contributed abstracts and this year we will be offering a 10% discount to the 3 day conference price, for anyone selected for an oral presentation. Please note the earlier deadlines:
- Oral Abstract: 18th November 2016
- Poster Abstract: 27th February 2017
We welcome abstracts on any subject but would be particularly interested in the following:
- Innovative Approaches to Rare Diseases
- Bayesian Topics Within Early or Late Phase
- Examples of Utilizing Big Data
- Case Studies Involving Innovative Designs/Methodology
- Advances in Early Phase Development
- Case Studies Applying Estimands
- Challenges in Combination Trials (any disease area)
- Approaches to Development in China or Japan
- Case Studies Involving Translational Research
- Consideration in Cancer Immunotherapy
- Applications of the New ICH E17 Guideline to Plan/Design Multi-Regional Trials
In order to submit an abstract, please download a form from
We will also be holding two pre-conference training courses on the afternoon of Sunday 14th May 2017:
- Issues in Early Phase Drug Development
- Sample Size, Power, and Adaptive Trial Design for Late Stage Studies
Please keep an eye on the Events page of the PSI website as we will add more information of Conference activities as they become available.
Finally, sponsorship and exhibition opportunities will be announced shortly. Should your company be interested please contact Nigel Howitt (
[log in to unmask]) or Chris Watton on (
[log in to unmask]).